Skip to main content
. 2022 Jan 21;434:120155. doi: 10.1016/j.jns.2022.120155

Fig. 1.

Fig. 1

Adverse events reported by MS patients following a third dose of BNT162b2 COVID-19 vaccination. Numbers beside the bars represent the percentage of participants who reported the specified adverse event.